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Abstract
Background: Animal studies suggest that local adipocyte-mediated activity of the renin-angiotensin-aldosterone
system (RAAS) contributes to circulating levels, and may promote the development of obesity-related hypertension
in rodents.
Methods: We examined relations of systemic RAAS activity, as assessed by circulating plasma renin activity (PRA),
serum aldosterone level, and aldosterone:renin ratio (ARR), with specific regional adiposity measures in a large,
community-based sample. Third Generation Framingham Heart Study participants underwent multidetector
computed tomography assessment of SAT and VAT volumes during Exam 1 (2002 and 2005). PRA and serum
aldosterone were measured after approximately 10 minutes of supine rest; results were log-transformed for
analysis. Correlation coefficients between log-transformed RAAS measures and adiposity measurements were
calculated, adjusted for age and sex. Partial correlations between log-transformed RAAS measures and adiposity
measurements were also calculated, adjusted for standard CVD risk factors.
Results: Overall, 992 women and 897 men were analyzed (mean age 40 years; 7% hypertension; 3% diabetes). No
associations were observed with SAT (renin r = 0.04, p = 0.1; aldosterone r = -0.01, p = 0.6) or VAT (renin r = 0.03,
p = 0.2; aldosterone r = -0.03, p = 0.2). Similar results were observed for ARR, in sex-stratified analyses, and for BMI
and waist circumference. Non-significant partial correlations were also observed in models adjusted for standard
cardiovascular risk factors.
Conclusions: Regional adiposity measures were not associated with circulating measures of RAAS activity in this
large population-based study. Further studies are required to determine whether adipocyte-derived RAAS
components contribute to systemic RAAS activity in humans.
Background
Obesity, and in particular central obesity, is associated
with hypertension, increased cardiovascular risk, dia-
betes mellitus and chronic kidney disease [1]. Risk esti-
mates from population-based studies indicate that over
65% of hypertension cases may be directly attributable
to obesity [2]. Recent increases in the US prevalence of
diabetes and chronic kidney disease parallel similar
increases in obesity rates, and observational studies
demonstrate an association between increasing body
mass index (BMI) and these diseases [3-5]. Furthermore,
it is proposed that different adipose compartments are
associated with varying degrees of metabolic risk [6] and
that visceral adipose tissue (VAT) in particular may con-
fer increased risk [7].
The renin-angiotensin-aldosterone system (RAAS) is a
cascade of hormones that play a central role in fluid
homeostasis and the regulation of vascular resistance,
classically activated by the release of renin from the
juxta-glomerular apparatus in response to a variety of
stimuli, such as renal hypoperfusion [8]. Upregulation of
the RAAS has been shown to promote the development
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atherosclerosis, diabetic end organ damage and chronic
kidney disease [9]. Many diverse pathophysiologic
mechanisms are implicated, including the production of
pro-sclerotic and pro-fibrotic cytokines such as trans-
forming growth factor-b, the promotion of endothelial
dysfunction and hypertrophy of vascular beds, the
induction of glomerular hypertension [8] and bi-direc-
tional interaction with hyperglycemia-induced maladap-
tive pathways [9].
Adipose tissue, and VAT in particular, may be an
important source of non-classical RAAS activity. For
example, visceral fat expression of angiotensinogen
approximates that of the liver, classically considered the
main source of this enzyme [10], and concentrations of
angiotensinogen increase with increasing BMI [11]. Non-
classical RAAS activation may result from the activity of
lipid derived mediators (adipokines) such as comple-
ment-C1q TNF-related protein 1 (CTRP1) or adiponectin
[12]. For example, CTRP1 is expressed at high levels in
adipose tissue and has been shown to induce aldosterone
production and partially mediate angiotensin II-induced
aldosterone secretion in the obese Zucker rat [12]. In
humans, CTRP1 levels are increased in the serum of
hypertensive patients, as well as being highly expressed in
obese subjects [12]. BMI has also been shown to predict
plasma aldosterone concentrations in hypertensive sub-
jects [13], normotensive individuals on a high-salt diet
[14], and visceral adiposity is strongly associated with
increased blood pressure and hypertension [15].
In light of these observations, we hypothesized that
RAAS activity may be related to variation in regional adip-
osity. To investigate this, we examined relations of RAAS
activity, as assessed by circulating plasma renin activity
(PRA), serum aldosterone level and aldosterone:renin ratio
(ARR), with specific regional adiposity measures in a large,
community-based sample. Specifically, we calculated cor-
relations of waist circumference (WC), BMI, VAT and
subcutaneous adipose tissue (SAT) with PRA, aldosterone
and ARR, and calculated partial correlations adjusted for
factors known to be associated RAAS activity.
Methods
Study sample
The Framingham Heart Study was initiated in 1948 with
the enrollment of 5,209 residents of Framingham, Mas-
sachusetts [16]. In 1971, 5,124 offspring of the original
cohort participants and their spouses were enrolled,
forming the Framingham Offspring Study [17]. Most
recently, 4,095 Third Generation Study participants with
at least one parent in the Offspring cohort were enrolled
between 2002 and 2005 [18]. For the present study, par-
ticipants were drawn from the 4095 participants who
attended the first exam cycle of the Third Generation
Study cohort [15]. Exclusion criteria were weight > 350
pounds, pregnancy and age under 35 years for men and
under 40 years for women and the presence of CKD
(defined as an estimated glomerular filtration rate of <
60 ml/min/1.73
2 using the 4-variable MDRD equation
[19]). In addition, participants residing in the greater
New England area were preferentially included in the
CT study for logistical reasons. The institutional review
boards of the Boston University School of Medicine and
Massachusetts General Hospital approved the study pro-
tocol and all subjects provided written informed
consent.
Exposure assessment: Abdominal imaging and
measurement of WC, BMI, SAT and VAT
Contemporaneous abdominal imaging was performed
with using an 8-slice multidetector CT scanner (Light-
speed Ultra; General Electric, Milwaukee, WI) using a
standard protocol [20]. In brief, 25 contiguous 5-mm-
thick slices were acquired above the level of S1. To assess
SAT and VAT volumes, the abdominal muscular wall
separating visceral from subcutaneous fat compartments
was manually traced on acquired images and volumetric
assessments were made. Intra-reader and inter-reader
reproducibility was high, as assessed by 2 independent
readers using a subset of 100 randomly selected partici-
pants (interclass correlations of 0.997 for SAT and 0.992
for VAT) [20]. These measures have been validated in
prior analyses, with differential associations of these VAT
and SAT measures previously reported for insulin resis-
tance [21], adiponectin [22], markers of inflammation
and oxidative stress [23] and cardiometabolic risk factors
[15]. BMI was defined as weight (in kilograms) divided by
the square of height (in meters). WC was measured at
the level of the umbilicus.
Outcome assessment: PRA, Aldosterone and ARR
Morning fasting venous blood was drawn after approxi-
mately 10 minutes rest in a supine position. Participants
were instructed to take all routine medications. Whole
blood samples were centrifuged and the serum/plasma
fraction stored at -70 to -80°C until analysis. PRA (ng/mL/
hr) was measured using the GammaCoat Plasma Renin
Activity RIA Kit (DiaSorin). The inter-assay coefficient of
variation (CV) was 12.6%. Serum aldosterone (nanograms
per deciliter) was measured by radioimmunoassay (Quest
Diagnostics) [24]. ARR was calculated by dividing the
serum aldosterone level by the PRA.
Covariate assessment
Covariates were measured at the contemporaneous Fra-
mingham Heart Study examination. Fasting plasma glu-
cose, high-density lipoprotein (HDL) cholesterol, and
triglycerides were measured on fasting morning samples.
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126 mg/dL or treatment with either insulin or a hypogly-
cemic agent. Current smokers were defined by having
smoked at least 1 cigarette per day for the previous year.
Alcohol use was assessed by a physician interview and
dichotomized on the basis of consumption of more than
14 drinks per week in men or 7 drinks per week in
women. Women were considered menopausal if men-
struation had ceased for > 1 year. SBP and DBP were mea-
sured twice with participant seated after 5 minutes rest
and the average of two measures was used for analysis.
Hypertension was defined as systolic blood pressure ≥ 140
mm Hg, diastolic blood pressure ≥ 90 mm Hg, or anti-
hypertensive treatment.
Statistical analyses
SAT and VAT were normally distributed, whereas PRA,
aldosterone, ARR and triglycerides were all logarithmically
transformed to induce approximate normality. Pearson
correlation coefficients between continuous adiposity mea-
sures (WC, BMI, VAT, SAT) and log-transformed mea-
sures of RAAS activity (PRA, aldosterone, ARR) were
calculated, adjusting for age and sex. Further associations
were evaluated by generating partial correlation coeffi-
cients adjusted for standard covariates (age, sex, diabetes,
systolic blood pressure, hypertension treatment, HDL cho-
lesterol, log triglycerides and current smoking), as well as
covariates known to correlate with radiologic measures of
central adiposity (hormone replacement therapy, meno-
pausal state and alcohol use) [25]. Anthropometric mea-
sures (BMI or WC) were included in testing correlations
with VAT but not for SAT, to avoid co-linearity between
SAT and anthropometric indexes [15].
Four secondary analyses were performed. First, linear
regression was used to assess the relationship between
sex-specific quartiles of VAT and SAT and continuous,
log-transformed measures of RAAS activity. Second, we
used logistic regression to model the association of contin-
uous VAT and SAT measures with dichotomized mea-
sures of RAAS activity, using sex-specific 75
th percentile
values as cut-offs. Third, we performed a stratified analysis
using 3 categories of BMI (lean (BMI < 25), overweight
(BMI 25.1 - 29.9) and obese (BMI > 30). Finally, we per-
formed a secondary analysis restricted to participants not
taking antihypertensive treatment. All analyses were per-
formed using SAS Version 9.1.3 (SAS Institute), and a
two-tailed P value of 0.05 was considered statistically
significant. We did not revise P values to account for
multiple testing.
Results
Of the 4095 participants who attended the baseline
examination, 1,993 had CT scanning performed with
assessment of abdominal SAT and VAT volumes. Of
these, 7 were excluded due to the presence of CKD, 11
due to prevalent cardiovascular disease, 36 due to miss-
ing adiposity measures, 52 due to missing PRA measure-
ments and 4 due to missing covariates, leaving a final
study sample of 1,883 individuals, comprised of 992
women and 897 men. The mean age was 40 years
(Table 1); 7% had hypertension and 3% had diabetes.
The mean SAT volume was 2729 ± 1331 cm
3 and the
mean VAT volume was 1592 ± 905 cm
3.
Correlations With Adiposity Measures
Correlations of SAT, VAT, WC and BMI with log-trans-
formed measures of RAAS activity are shown in Table 2.
No associations were observed with SAT (log-renin r =
0.04, p = 0.1; log-aldosterone r = -0.01, p = 0.6), VAT
(log-renin r = 0.03, p = 0.2; log-aldosterone r = -0.03,
p = 0.2), BMI (log-renin r = 0.03, p = 0.2; log-aldoster-
one r = -0.04, p = 0.07) or waist circumference (log-
renin r = 0.04, p = 0.06; log-aldosterone r = -0.02, p =
0.4) in the overall sample, or in sex-stratified analyses.
Table 1 Study sample characteristics: Data are means ±
SD (normally distributed continuous variables), median
(interquartile range) (continuous variables that are not
normally distributed), or percent (n)
Clinical measures
N 1889
Age (years) 40 (9)
Women, % 992 (53)
Systolic blood pressure (mmHg) 116 (14)
Hypertension treatment, % 139 (7)
Current smoker, % 323 (17)
Diabetes, % 62 (3)
Postmenopausal, % of women 85 (9)
Hormone Replacement Therapy, % of women 44 (4)
Alcohol use*, % 550/1830 (30)
HDL cholesterol (mg/dl) 54 (16)
Triglycerides (mg/dl) 91 (79, 170)
Biochemical measures
Plasma renin activity (ng/mL/hr) 2.3 (1.1, 2.7)
Serum aldosterone (ng/dL) 12.7 (8.5, 15.0)
Adiposity measures
Body Mass Index (kg/m
2) 26.6 (5.4)
Overweight (Body Mass Index 25-30 kg/m
2) 645 (34)
Obese (Body Mass Index > 30 kg/m
2) 409 (22)
Waist circumference (cm) 96 (13)
Subcutaneous Adipose Tissue (cm
3) 2729 (1331)
Visceral Adipose Tissue (cm
3) 1592 (905)
*Defined as > 14 drinks/week
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Results of partial correlation tests for SAT, VAT, WC
and BMI are shown in Table 3. No significant association
between log-renin and SAT (p = 0.1), VAT (p = 0.2),
BMI (p = 0.7) or WC (p = 0.06) was observed. Also, no
significant associations were observed for log-aldosterone
and SAT (p = 0.7), VAT (p = 0.2), BMI (p = 0.8) or WC
(p = 0.4). Additional adjustment for specific adiposity
measures (BMI or VAT) did not significantly affect the
results. We determined that we had 80% power to detect
a correlation of 0.065, if it truly existed.
Secondary analyses
Following the negative results of the primary analysis, we
tested the association of quartiles of VAT and SAT and
continuous RAAS measures in linear regression models.
No significant association was observed for either VAT
(multivariable-adjusted relations of uppermost vs. lower-
most quartile and log aldosterone concentration: p = 0.2)
Table 2 Age-, and sex-adjusted Pearson correlation coefficients (r) of adiposity measures and log-aldosterone to renin
ratio, log-aldosterone and log-renin; overall and stratified by sex
Log-renin Log-aldosterone Log-aldosterone: renin
r P-value r P-value r P-value
Overall
Body Mass Index 0.03 0.2 -0.04 0.07 0.04 0.04
Waist circumference 0.04 0.06 -0.02 0.4 0.05 0.03
Subcutaneous Adipose Tissue 0.04 0.1 -0.01 0.6 0.04 0.1
Visceral Adipose Tissue 0.03 0.2 -0.03 0.2 0.04 0.06
Men
Body Mass Index 0.02 0.6 -0.05 0.2 0.04 0.2
Waist circumference 0.02 0.5 -0.06 0.06 0.05 0.1
Subcutaneous Adipose Tissue 0.01 0.8 -0.04 0.2 0.03 0.4
Visceral Adipose Tissue 0.00 1.0 -0.05 0.1 0.03 0.4
Women
Body Mass Index 0.04 0.2 -0.04 0.2 0.06 0.07
Waist circumference 0.06 0.05 0.02 0.6 0.04 0.2
Subcutaneous Adipose Tissue 0.06 0.06 0.01 0.6 0.04 0.2
Visceral Adipose Tissue 0.06 0.05 -0.01 0.8 0.06 0.07
Table 3 Partial correlation coefficients (r) between adiposity measures and log-aldosterone to renin ratio, log-
aldosterone and log-renin, adjusted for cardiovascular risk factors
Log-renin Log-aldosterone Log-aldosterone: renin ratio
r P-value r P-value r P-value
SAT
Multivariable-adjusted 0.03 0.1 -0.01 0.7 0.04 0.1
VAT
Multivariable-adjusted 0.03 0.2 -0.03 0.2 0.04 0.05
Multivariable-adjusted + BMI 0.03 0.1 -0.03 0.2 0.05 0.04
Multivariable-adjusted + SAT 0.02 0.4 -0.03 0.2 0.03 0.1
BMI
Multivariable-adjusted 0.01 0.7 -0.01 0.8 0.01 0.6
Multivariable-adjusted + VAT 0.01 0.8 -0.01 0.6 0.01 0.6
Waist circumference
Multivariable-adjusted 0.04 0.06 -0.02 0.4 0.05 0.04
Multivariable-adjusted + VAT 0.03 0.2 0.01 0.7 0.02 0.4
*Multivariable-adjusted for age, sex, diabetes, systolic blood pressure, hypertension treatment, HDL-cholesterol, log triglycerides, menopause status, hormone
replacement therapy and current smoking.
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lowermost quartile and log-aldosterone concentration
p = 0.7) in this analysis.
In a logistic regression model of continuous SAT and
VAT measures with dichotomized measures of RAAS
activity (using the 75
th percentile as a cut-point), no sig-
nificant association was observed for either SAT or
VAT and plasma renin level (multivariable-adjusted
odds ratio [OR] of the uppermost quartile of renin con-
centration per standard deviation increment in SAT was
1.10 (95% confidence interval [CI] 0.99 - 1.22; p-value =
0.07) and VAT was 1.09 (95% CI 0.99 - 1.21; p-value =
0.09) or plasma aldosterone level (OR per standard
deviation increase in SAT was 0.93 (95% CI 0.84 - 1.02;
p-value = 0.2) and VAT was 0.92 (95% CI 0.84 - 1.02;
p-value = 0.1).
In a stratified analyses using sub-categories of BMI
(lean (BMI < 25), overweight (BMI 25.1 - 29.9) and obese
(BMI > 30), we observed a weak correlation between
renin activity and renin: aldosterone ratio and SAT in
lean individuals (r for plasma renin and SAT 0.08; p-
value 0.03; r for renin: aldosterone ratio and SAT 0.08; p-
value 0.03). There were no significant correlations apart
from this, similar to the primary analysis.
Finally, apart from a weak association between renin:
aldosterone ratio and BMI (r = 0.05; p-value 0.04),
results of analyses undertaken in participants not taking
antihypertensive treatment were essentially unchanged
from the primary analysis, with no significant correla-
tions observed.
Discussion
Contrary to our original hypothesis, we did not observe
an association between any specific adiposity measure
and activity of the RAAS system in overall, sex-stratified
or multivariable-adjusted analyses.
Angiotensinogen, renin (or peptides with renin-like
activity), angiotensin converting enzyme (ACE), and AT1
and AT2 receptors are all secretory products of the rodent
adipocyte [26], and the expression of some are increased
in obesity [27,28]. Although their primary function is not
known, autocrine/paracrine tissue effects on adipocyte
function are well described [29,30]. In addition, studies in
transgenic mice demonstrate that adipose-derived angio-
tensinogen may also contribute to the systemic RAAS
pool, and the relationship between obesity and hyperten-
sion may be directly explained by angiotensinogen secre-
tion by the rodent adipocyte [31].
As in rodents, multiple lines of evidence support the exis-
tence of adipocyte RAAS in humans [30], and the present
findings do not preclude the existence of significant local
RAAS activity in our sample. However, evidence that the
human adipose RAAS makes a significant contribution to
systemic activity has not been convincingly demonstrated,
and the literature in this area is conflicting. For example, a
study in lean, healthy, young men (n = 91) did demonstrate
a correlation between plasma angiotensinogen levels and
BMI (r = 0.33, P < 0.05), whereas no significant correlation
with PRA or circulating aldosterone levels was observed
[11]. In a second study of 38 obese vs. lean postmenopausal
women, circulating levels of angiotensinogen, renin, aldos-
terone and angiotensinogen converting enzyme (ACE)
were significantly higher in the obese women, and plasma
levels of several RAAS peptides decreased after weight loss
[32]. However, in contrast to our population-based study,
morbidly obese cases were selected for this analysis (mean
BMI 38 kg/m
2), making direct comparison with our study
difficult. It is possible that unaccounted factors may have
influenced RAAS levels in that study; for example, there
was evidence of substantial insulin resistance in cases,
which has been shown to be independently associated with
RAAS activity in many studies [33-37]. A third study also
detected a correlation between BMI and plasma aldoster-
one concentrations in overweight and obese patients with
essential hypertension [13]. However, this was conducted in
a tertiary referral hypertension clinic, and is not directly
comparable with the present analysis. Furthermore, several
studies in obese individuals with hypertension have not
detected an association between obesity and circulating
RAAS components [38-40].
The present work extends the literature in several ways.
In contrast to evidence from animal models, where adi-
pocyte RAAS exerts substantial physiologic action
beyond the local environment of the adipocyte [29], our
findings suggest that adipose RAAS does not make a sub-
stantial contribution to the systemic RAAS pool in the
general population. There are several potential reasons
for this. First, substantial inter-species differences in fat
deposits and metabolism exist between rodents and
humans [41]. For example, whereas angiotensin II pro-
motes adipocyte growth and pre-adipocyte recruitment
in rodents, it is anti-adipogenic in human adipose tissue
[41]. Furthermore, in contrast to rodent models of diet-
induced obesity, angiotensinogen mRNA expression in
the adipose tissue of obese, hypertensive females is not
greater than that of non-obese controls [30]. Fundamen-
tal inter-species differences in adipocyte biology such as
these may preclude the extension of observations made
in the rodent to humans. Equally, even if observations
made in obese rodents are reflective of human pathophy-
siology, the cross-sectional design of our study may fail
to capture dynamic changes in RAAS components due to
active weight gain. For example, changes in the expres-
sion of RAAS components following sudden, controlled
weight gain in rodents may not be observed during
chronic, stable obesity, which may be more representative
of the participants in our study. As discussed, significant
changes in circulating RAAS components have been
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[32]. Finally, it may be that adipose RAAS functions pri-
marily in a paracrine/autocrine manner, and systemic
levels are not reflective of local tissue activity in humans.
Several avenues for further study are suggested by the
present analysis. In particular, efforts to delineate the
relative importance of adipocyte-derived (as compared
to classically-derived) RAAS components, and their rela-
tive contribution to circulating levels, are required; adi-
pocyte-specific RAAS component knockout models
would be most helpful in this regard. Human studies
comparing tissue mRNA expression of RAAS compo-
nents during weight gain as compared to chronic obesity
and lean controls may also prove illuminating.
The use of an unselected, community-based sample,
t h eh i g h l yr e p r o d u c i b l ev o l umetric method of assessing
SAT and VAT, and the sample size sufficient to power
multivariable analyses comparing the relative magnitudes
of association strengthen our study. However, several
limitations should also be acknowledged. Ambulatory
RAAS measurements were drawn from individuals on a
free-living sodium diet, while taking their usual antihy-
pertensive medications, potentially biasing our results
toward the null. As sodium balance is a major determi-
nant of renin and aldosterone, the absence of data on
sodium intake and urinary excretion is an important lim-
itation. However, it should be noted that results were
similar to the primary analysis in participants not taking
anti-hypertensive treatment. Furthermore, samples were
drawn after only 10 minutes in the supine position, and
not after 1 h of rest as recommended in research unit
protocols, which are impractical in the setting of a large,
longitudinal observational cohort. Our analysis would be
enhanced by directly measuring markers of local RAAS
activation in adipose tissue. However, this is unfortu-
nately not technically feasible in a large, observational
epidemiologic study. Finally, our results may not be gen-
eralizable to all racial/ethnic groups or age groups, as our
sample was primarily white and middle-aged, and racial
differences in serum aldosterone and renin values have
been reported [42].
Conclusions
In conclusion, regional adiposity measures were not
associated with systemic RAAS activity, as determined
by plasma renin activity, serum aldosterone concentra-
tion and aldosterone to renin ratio, in this large popula-
tion-based study. Further studies are required to
establish whether adipose-derived RAAS components
contribute to systemic activity in humans.
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